相关临床试验
0
0 进行中
药物批准
55
批准总数
监管机构
2
监管机构数
成立时间
1921
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Jubilant Pharmova received US FDA approval on August 22 for commercial batch manufacturing of the first product on Line 3, a new isolator-based fill-and-finish line at its Spokane, Washington facility. - Line 3 is operated by Jubilant HollisterStier LLC (JHS), a subsidiary focused on sterile injectables and ophthalmic contract manufacturing for pharmaceutical and biopharmaceutical companies. - The approval supports Jubilant Pharmova's CDMO Sterile Injectables segment, which reported 34% revenue growth to ₹496 crore in Q1FY27, with Spokane facility revenue up 43% to ₹494 crore. - The company's profitability was pressured by the absence of high-margin SPECT radiopharmaceutical products and higher operating expenses, including Montreal remediation costs.
- Jubilant HollisterStier LLC has successfully commissioned its third sterile fill and finish line at its Spokane facility with a $132 million investment, featuring advanced isolator technology for enhanced sterility assurance. - The new production line adds 50% manufacturing capacity to the facility and is expected to reach full utilization within three years amid strong demand from major pharmaceutical companies. - With a fourth line planned, the company is on track to double its total sterile injectable manufacturing capacity, creating hundreds of new jobs and strengthening the U.S. pharmaceutical supply chain. - The expansion comes as large innovator pharma companies seek high-quality U.S. manufacturing facilities following new government tariffs, with JHS experiencing strong traction in requests for proposals.
